Iraq vs Mozambique: Average cost of multi drug-resistant tuberculosis treatment
Iraq
1,500 constant 2022 US$
in 2024
Mozambique
1,250 constant 2022 US$
in 2024
Iraq rank
34th
Mozambique rank
37th
Average cost of multi drug-resistant tuberculosis treatment over time
- Iraq
- Mozambique
How they compare
Iraq currently reports 1,500 constant 2022 US$ against 1,250 constant 2022 US$ in Mozambique, a difference of 250 constant 2022 US$.
That makes Iraq's figure about 1.2 times Mozambique's.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Iraq ahead.
Iraq ranks 34th and Mozambique ranks 37th of 92 countries.
Across the 2 decades both report, Iraq averaged higher in 1 and Mozambique in 1.
Head to head by decade
| Decade | Iraq | Mozambique | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,000 constant 2022 US$ | 3,095 constant 2022 US$ | 905 constant 2022 US$ | Iraq |
| 2020s | 2,300 constant 2022 US$ | 2,464 constant 2022 US$ | 163.8 constant 2022 US$ | Mozambique |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Iraq or Mozambique?
- Iraq, at 1,500 constant 2022 US$ against 1,250 constant 2022 US$ in Mozambique as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Iraq and Mozambique?
- 250 constant 2022 US$, with Iraq ahead.
- How many years of comparable data are there for Iraq and Mozambique?
- 8 years are reported by both, from 2017 to 2024.
- How do Iraq and Mozambique rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Iraq ranks 34th and Mozambique ranks 37th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.